Woodline Partners LP Has $39.34 Million Holdings in Janux Therapeutics, Inc. $JANX

Key Points

• Woodline Partners LP has decreased its stake in Janux Therapeutics, Inc. by 21.3% in the 1st quarter, selling 395,092 shares and now owning approximately 2.46% of the company worth $39,342,000.
• Analysts have set a positive outlook for Janux Therapeutics, with an average rating of "Buy" and an average target price of $85.55.
• Janux Therapeutics reported a loss of ($0.55) per share in its latest earnings results, which was below analysts' expectations of ($0.48) per share.

Woodline Partners LP lowered its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 21.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,457,095 shares of the company's stock after selling 395,092 shares during the quarter. Woodline Partners LP owned approximately 2.46% of Janux Therapeutics worth $39,342,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. RA Capital Management L.P. grew its holdings in Janux Therapeutics by 7.9% during the 1st quarter. RA Capital Management L.P. now owns 11,189,693 shares of the company's stock worth $302,122,000 after acquiring an additional 824,041 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Janux Therapeutics by 19.4% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,654,574 shares of the company's stock valued at $98,673,000 after purchasing an additional 592,824 shares during the last quarter. Paradigm Biocapital Advisors LP boosted its stake in shares of Janux Therapeutics by 46.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company's stock valued at $188,246,000 after purchasing an additional 1,115,412 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Janux Therapeutics by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company's stock valued at $61,524,000 after purchasing an additional 142,328 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Janux Therapeutics by 25.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,392,826 shares of the company's stock valued at $37,607,000 after purchasing an additional 282,848 shares during the last quarter. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Stock Performance

JANX stock traded down $1.07 during mid-day trading on Friday, hitting $24.05. 511,570 shares of the company were exchanged, compared to its average volume of 613,391. The firm has a market cap of $1.45 billion, a P/E ratio of -13.36 and a beta of 2.84. The firm's 50 day simple moving average is $24.58 and its 200 day simple moving average is $26.38. Janux Therapeutics, Inc. has a 1-year low of $21.97 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.07). On average, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Raymond James Financial assumed coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 target price on the stock. Truist Financial assumed coverage on shares of Janux Therapeutics in a research note on Wednesday. They issued a "buy" rating and a $100.00 target price on the stock. Piper Sandler began coverage on shares of Janux Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $42.00 target price on the stock. Stifel Nicolaus reissued a "buy" rating and set a $45.00 price objective on shares of Janux Therapeutics in a research note on Wednesday. Finally, Guggenheim began coverage on shares of Janux Therapeutics in a research note on Wednesday, September 3rd. They set a "buy" rating and a $72.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $80.92.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.